Design Therapeutics, Inc. (DSGN) vs Lexicon Pharmaceuticals, Inc. (LXRX)
A side-by-side comparison of Design Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DSGN
Design Therapeutics, Inc.
$12.01HealthcareDelayed quote: Oct 6, 2026, 10:25 AM EDT
LXRX
Lexicon Pharmaceuticals, Inc.
$1.73HealthcareDelayed quote: Oct 6, 2026, 10:25 AM EDT
Total return — DSGN vs LXRX
growth of $100 · dividends reinvested · last 6yDSGN -70.1% (-18.2%/yr)LXRX -71.9% (-19.1%/yr)DSGN compounded faster over this window
DSGN LXRX
DSGN vs LXRX: by the numbers
- •LXRX is the larger company ($769M vs $750M market cap).
- •Both run net losses; DSGN's is the smaller (0.00% vs -147.38% net margin).
Metrics side by side
Valuation
| Metric | DSGN | LXRX |
|---|---|---|
| P/S ratio | N/A | 18.53 |
| P/B ratio | 3.72 | 4.40 |
Profitability
| Metric | DSGN | LXRX |
|---|---|---|
| Gross margin | 0.00% | 98.85% |
| Operating margin | 0.00% | -98.21% |
| Net margin | 0.00% | -147.38% |
| ROE | -35.07% | -35.02% |
| ROIC | -38.92% | -23.16% |
Growth (annualized)
| Metric | DSGN | LXRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 42.36% |
| Total return CAGR (5Y) | -3.82% | -18.54% |
Frequently asked
- How have DSGN and LXRX total returns compared?
- Over the past 5 years, DSGN delivered -3.82% and LXRX delivered -18.54% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Design Therapeutics ROELexicon Pharmaceuticals ROEDesign Therapeutics operating marginLexicon Pharmaceuticals operating marginDesign Therapeutics revenue growthLexicon Pharmaceuticals revenue growthDesign Therapeutics free cash flowLexicon Pharmaceuticals free cash flow
Design Therapeutics & Lexicon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.